Market need Medio Labs offers MedioSeq, a converged NGS workflow that promises higher throughput and lower costs for pathogen detection labs. This represents a clear opportunity to sell to facilities currently using qPCR with expansion needs in human, veterinary, environmental, and food testing markets.

Scale potential The platform has demonstrated capacity to process thousands of Covid-19 samples per day, signaling strong scalability. Target labs looking to increase panel throughput and reduce space, personnel, and instrument requirements are likely to be receptive.

Cost efficiency By consolidating multiple qPCR panels into a single NGS workflow, MedioSeq positions itself as a cost- and resource-saving solution. This could be a compelling ROI driver for labs facing budget pressures and staffing constraints.

Expansion opportunities Applications span human diagnostics and diverse sectors (veterinary, agricultural, environmental, food testing), suggesting multiple adjacent market segments for upsell and cross-sell of MedioSeq with minimal workflow changes.

Engagement path With a lean team and a direct outreach channel (info@medio.ai), potential buyers can be engaged through targeted pilots, demonstrations, and streamlined onboarding to validate throughput gains and cost savings quickly.